Chin Med J (Engl) March 2023 PMID 36914945

Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease.

Xianfeng Yu, Kai Shao, Ke Wan, Taoran Li, Yuxia Li, Xiaoqun Zhu, Ying Han

Download social card

Mentions

Peak: 1 in Jul 2023

across 2 sources since Jul 2023

Extended reach

473

potential audience

Total likes

Video views

Mentions per month

Jul 2023 – Aug 2023

Where it's discussed

X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

Several discussions highlight the significance of developing blood tests for preclinical Alzheimer's, using phrases like 'potential breakthrough' and 'hope for early diagnosis,' suggesting interest and engagement. However, some comments express skepticism about the reliability or practicality, which supports the neutral agreement and impact scores, as the overall tone is cautiously optimistic but not overwhelmingly supportive or dismissive.

AgreementNeither agree nor disagree

Discussions show mixed opinions; some express support for the research, while others remain cautiously optimistic or skeptical about the findings and their clinical applications.

InterestModerate interest

Most comments indicate a moderate level of curiosity, with some users expressing interest in the implications of blood biomarkers for early detection.

EngagementModerate engagement

Comments often reference specific challenges and potential, suggesting active engagement, though some posts are brief and not deeply analytical.

ImpactNeutral impact

The discussions reflect an awareness of the importance of early detection methods, but generally lack widespread advocacy or calls for immediate change.

Abstract in brief

This article discusses how Alzheimer's disease (AD) is now viewed as a continuous process rather than just a condition reaching a certain stage, emphasizing the importance of detecting it early, especially during the stage called subjective cognitive decline (SCD), where people feel their memory is worsening but still perform normally.
Current diagnostic methods like cerebrospinal fluid tests and brain imaging are invasive and costly, so developing simple, affordable blood tests could help identify early AD more easily and widely.
The review highlights the progress and challenges in finding reliable blood biomarkers to detect preclinical AD in individuals with SCD, given the complex nature of the disease which makes it hard to rely on a single marker for diagnosis.

Read the full abstract

All mentions

Advances in Blood Biomarkers for Early Detection of Alzheimer's Disease

This video discusses early detection of Alzheimer's disease during subjective cognitive decline using blood biomarkers, highlighting recent progress and challenges in developing affordable, non-invasive diagnostic tools.

Medicine RTCL TV · Jul 24, 2023 33 views

CMJ

@ChinMedJ · X

Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease https://t.co/30vQNfHc6a

Aug 15, 2023 · 440 followers View post →